NeuroOne Medical Technologies Corp (NMTC) Stock Analysis
Verdict: AVOID
Commercialization scaling is insufficient to offset the burn rate, necessitating further dilution that will cap near-term upside.
Investment score: 38/100
Analysis as of
Is NeuroOne Medical Technologies Corp stock worth reviewing? AI model thesis
The AI model sees a micro-cap in a classic 'liquidity trap' where improving fundamentals are ignored due to the threat of dilution.
7-factor investment score
- Valuation: 45/100 (weight 20%)
- Financial Health: 30/100 (weight 15%)
- Technical Momentum: 15/100 (weight 15%)
- Earnings Quality: 50/100 (weight 15%)
- Insider Sentiment: 25/100 (weight 10%)
- Analyst Consensus: 75/100 (weight 10%)
- Risk-Adjusted Return: 40/100 (weight 15%)
NeuroOne Medical Technologies Corp opportunities and risks
What speaks for NMTC
- 2029 Profitability Pivot
What speaks against NMTC
- Immediate Dilution Risk
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| NMTC | n/a | 1.8x | n/a | 54.5% | -68.3% | -42.2% |
| GTHP | n/a | 27.0x | n/a | 67.9% | -512.6% | -6.5% |
| CTSO | n/a | 0.7x | n/a | 71.0% | -31.9% | -40.5% |
| RDGL | n/a | 347.4x | n/a | -275.6% | -4396.3% | -8.5% |
| GIPL | n/a | 166.6x | n/a | 86.7% | -474.2% | -1.7% |
| IRIX | n/a | 0.3x | n/a | 36.1% | -6.2% | -15.5% |
| Peer median | n/a | 27.0x | n/a | 67.9% | -474.2% | -8.5% |
Frequently asked questions about NeuroOne Medical Technologies Corp (NMTC)
Is NMTC stock a good investment?
The cached TradeMates AI model rates NeuroOne Medical Technologies Corp as AVOID with an investment score of 38/100. The AI model sees a micro-cap in a classic 'liquidity trap' where improving fundamentals are ignored due to the threat of dilution. This is algorithmic model output, not personal investment advice.
Is NMTC stock a buy?
The TradeMates model verdict for NMTC is AVOID with an investment score of 38/100. Treat this as a model signal to review, not a personal buy recommendation.